Watch INBX. Know when insiders buy.
One email the day a filing lands. Free.
INBX
Inhibrx Biosciences, Inc.
114.34
−6.83 −5.64%
USD · close Sep 8
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
80
PASS · insiders 100, shorts 60
Insiders, 90 days
+$3.5M
net buying · 8 buys, 0 sells · cluster
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $1.7BP/E —DIV YIELD —FCF YIELD -7.84%REV TTM —NET INCOME −$138.2MNET DEBT $42.9M52W 26.53 – 141.84SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $0 | −100.0% | — | −$32.1M | −$36.6M | — | -2.34 | −$29.9M | $0 | −$29.9M | Aug 13 |
| Q1 2026 · Mar 31 | — | — | — | −$30.9M | −$33.4M | — | -2.15 | −$38M | $0 | −$38M | Aug 13 |
| Q4 2025 · Dec 31derived | $0 | −100.0% | — | −$30.9M | −$32.8M | — | -2.11 | −$30.1M | $0 | −$30.1M | Mar 19 |
| Q3 2025 · Sep 30 | $0 | — | — | −$33.8M | −$35.3M | — | -2.28 | −$33.8M | $10K | −$33.8M | Nov 14 |
| Q2 2025 · Jun 30 | $1.3M | +1200.0% | — | −$27.4M | −$28.7M | −101.5% | -1.85 | −$30M | $0 | −$30M | Aug 13 |
| Q1 2025 · Mar 31 | $0 | — | — | −$42.9M | −$43.3M | — | -2.80 | −$35.9M | $21K | −$35.9M | Aug 13 |
| Q4 2024 · Dec 31derived | $100K | −93.9% | — | −$49.9M | −$47.9M | — | -4.47 | −$43.7M | $16K | −$43.7M | Mar 19 |
| Q3 2024 · Sep 30 | $0 | −100.0% | — | −$46.8M | −$43.9M | — | -2.84 | −$30.3M | $247K | −$30.5M | Nov 14 |
| Q2 2024 · Jun 30 | $100K | — | — | −$160.9M | $1.9B | — | 125.48 | −$57.4M | $1.2M | −$58.6M | Nov 14 |
| Q1 2024 · Mar 31 | $0 | — | — | −$73.8M | −$78.7M | — | -5.77 | −$63M | $1.1M | −$64.2M | Nov 14 |
| Q4 2023 · Dec 31derived | $1.6M | — | — | −$88.3M | −$93.6M | — | -7.29 | −$56.8M | $3.4M | −$60.3M | Mar 17 |
| Q3 2023 · Sep 30 | $119K | — | — | −$45.8M | −$51.8M | — | -4.39 | −$54.2M | $811K | −$55.1M | Nov 14 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $1.3M | — | −$135M | −$140.1M | -10773.5% | -9.04 | −$129.8M | $31K | −$129.8M | — | — |
| FY2024 · to Dec 31 | $200K | — | −$331.4M | $1.7B | 843786.0% | 112.62 | −$194.4M | $2.6M | −$197M | — | — |
| FY2023 · to Dec 31 | $1.8M | — | −$219.2M | −$241.4M | -13408.9% | -20.48 | −$193.3M | $4.6M | −$197.9M | — | — |
Every number comes from Inhibrx Biosciences, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.